07:42 AM EDT, 10/27/2025 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said Monday it has launched a phase 1 single ascending dose and multiple ascending dose study of its investigational schizophrenia treatment NMRA-898.

The study will evaluate the safety, tolerability, and human pharmacokinetic impact of the drug, the company said.

The company said it expects to provide an update for NMRA-898 and another candidate, NMRA-861, within its M4 schizophrenia franchise by mid-2026.

Shares of the company were up more than 1% in recent premarket activity Monday.